Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology
Volume 18 (2004), Suppl B, Pages 3B-8B

Gastrointestinal Stromal Tumours: Etiology, Pathology and Clinical Management

Martin E Blackstein,1 Pierre Dubé,2 Jonathan A Fletcher,3 Oliver R Keller,4 Margaret Knowling,5 Richard Létourneau,6 Donald Morris,7 Robert Riddell,1 Stewart Rorke,8 Carol J Swallow,1 and Canadian Advisory Committee on GIST1

1Mount Sinai Hospital, Toronto, Ontario, Canada
2Centre Hospitalier Maisonneuve-Rosemont, Montreal, Quebec, Canada
3Brigham and Women’s Hospital, Boston, Massachusetts, USA
4Ottawa Regional Cancer Centre, Ottawa, Ontario, Canada
5British Columbia Cancer Agency – Vancouver Cancer Clinic, Vancouver, British Columbia, Canada
6Centre Hospitalier de l’Université de Montréal, Montreal, Quebec, Canada
7Tom Baker Cancer Centre, Calgary, Alberta, Canada
8Dr H Bliss Murphy Cancer Centre, St John’s, Newfoundland, Canada

Copyright © 2004 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Investigation of the regulation of cell growth, differentiation and death by signalling pathways has led to a greater understanding of how alterations in these pathways play a critical role in the development of some cancers, and has opened new opportunities for their treatment. In the present review, results with the prototype drug of this class, imatinib (Gleevec, Glivec [formerly STI571]; Novartis, Switzerland), in metastatic gastrointestinal stromal tumours are presented. The present review originated from a conference of the authors held in Montreal, Quebec in June 2003, under the sponsorship of Novartis.